Skip to main content
Clinical Trials/NCT03327454
NCT03327454
Completed
Not Applicable

Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen

Biogen1 site in 1 country500 target enrollmentAugust 10, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
Biogen
Enrollment
500
Locations
1
Primary Endpoint
Percentage of Participants that are "Very Satisfied (4)" or "Satisfied (3)" with the Benepali Pre-Filled Pen
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The main aim of this study is to ascertain general satisfaction among participants with rheumatic diseases with day-to-day use of the Benepali® prefilled pen by means of a standardised participant questionnaire. In addition, it is to be investigated whether differences exist in general participant satisfaction between participant groups who have undergone various prior treatment and/or have previous experience with application systems (participants new to the use of biologics, participants changing over from a prefilled injection or changing over from another pre-filled pen) and between participants of the various indication groups. Furthermore, the participants are to evaluate various aspects of using the Benepali® pre-filled pen based on their personal experience, such as e.g. handling, user-friendliness and features of the Benepali® pre-filled pen, as well as the effectiveness of the training on injection with the Benepali® pre-filled pen, based on participant satisfaction with the training received with the training pen and the evaluation of the training material received.

Registry
clinicaltrials.gov
Start Date
August 10, 2017
End Date
June 21, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Biogen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of moderate to severe active rheumatoid arthritis, severe active and progressive rheumatoid arthritis, active and progressive psoriatic arthritis, severe active ankylosing spondylitis, or severe non-radiographic axial spondyloarthritis
  • Current treatment with the Benepali® pre-filled pen in accordance with prescribing information for at least 3 months beforehand
  • The patient has signed a declaration of consent to take part in the study

Exclusion Criteria

  • Patients who are receiving Benepali® for the treatment of moderate to severe plaque psoriasis
  • Patients who exhibit contraindications in accordance with the prescribing information for Benepali® and therefore treatment with Benepali ® is not indicated
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Outcomes

Primary Outcomes

Percentage of Participants that are "Very Satisfied (4)" or "Satisfied (3)" with the Benepali Pre-Filled Pen

Time Frame: Day 1

The Questionnaire is based on a 5-point Likert scale where 0 = very dissatisfied, 1 = dissatisfied, 2 = neither dissatisfied nor satisfied, 3 = satisfied, 4 = very satisfied.

Secondary Outcomes

  • Percentage of Participants that Answered Questions on Their Personal Experience of Various Aspects of Using the Benepali Pre-Filled Pen with a (3) or (4) on a 5-point Likert Scale.(Day 1)
  • Percentage of Participants that Answered "Yes" in Terms of Satisfaction with Training Materials(Day 1)

Study Sites (1)

Loading locations...

Similar Trials